Abiopharma

🔍 Schneiderman Daniel H (Executive)

Company: Pasithea Therapeutics Corp. (KTTA)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 1,129,323 shares of Stock Option (right to buy) at $0.841 per share (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2036-04-30 | equity_swap_involved: 0 | shares_owned_after: 1,129,323.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan).